Drug prevents severe cardiac events in children undergoing chemotherapy for AML

(Children's Hospital of Philadelphia) The cardioprotective drug dexrazoxane preserved cardiac function in pediatric patients undergoing chemotherapy for acute myeloid leukemia (AML) without compromising overall patient survival and potentially improving it, according to a new study by researchers at Children's Hospital of Philadelphia (CHOP). The results suggest dexrazoxane should be considered for cardioprotection in all pediatric patients undergoing standard chemotherapy for AML.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news